Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats

Yamada, Koji; Horita, Takako Kadowaki; Takayama, Makoto; Takahashi, Shun; Takaba, Katsumi; Nagata, Yoshinori; Suzuki, Norihiro; Kanda, Tomoyuki

doi:10.1016/j.brainres.2011.09.016

Cited by 50 publications

(43 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The similar pharmacologic effects of the ACE inhibitors on cognitive function were also found in recent clinical trials [9][10][11] and in animal models [12,13]. It is noteworthy that some studies denoted that the direct effects of the ACE inhibitors to lower the risk of developing dementia could be independent from the controlling of cardiovascular disease and blood pressure control [2,4,14].…”

supporting

confidence: 68%

Pharmarcogenetic Mechanism of ACE I/D Polymorphism Adversely Responding to ACE Inhibitors in Regulating the ACE Promoter Activity in Neurons

Yang¹,

Chang²,

Chang³

et al. 2016

JPP

View full text Add to dashboard Cite

Abstract:The ACE (angiotensin converting enzyme) inhibitors are not only drugs widely prescribed drugs in cardiovascular diseases, but also potentially therapeutic agents in dementia. Based on the findings that the ACE inhibitors could activate the c-Jun N-terminal kinase signal to increase the ACE gene expression and that the Alu element of the human ACE gene involved in regulating ACE promoter activity, we aimed to investigate whether there are different pharmacogenetic responses of ACE I/D polymorphism to the ACE inhibitors in neurons. The three reporter vectors, pACEpro(f)-SEAP, p-I-ACEpro-SEAP, and p-D-ACEpro-SEAP were used to examine the transcriptional activity of the vectors responding to the lisinopril treatment using a transient-transfection method in SH-SY5Y cells. Our results showed that lisinopril increased the promoter activity of an ACE gene by 16.7%. Additionally, we found the lisinopril enhanced the ACE promoter activity of the I-form vector by 17.2%, but adversely reduced that of the D-form vector by 16.8%, as compared with the respective control without the lisinopril treatment. Firstly, our findings had proved that the I/D polymorphism of ACE gene contrarily responds to the ACE inhibitors in regulating the ACE expression in neurons, which provide a novel insight suggesting genetic testing to tailor the treatment regimens in AD (Alzheimer's disease) patients.

show abstract

supporting

confidence: 68%

Pharmarcogenetic Mechanism of ACE I/D Polymorphism Adversely Responding to ACE Inhibitors in Regulating the ACE Promoter Activity in Neurons

Yang¹,

Chang²,

Chang³

et al. 2016

JPP

View full text Add to dashboard Cite

show abstract

“…34,35 We did not conduct a controlled clinic trial, did not control for dosage levels, and did not examine improvment in performance in this crosss-sectional, treatment-as-usual study. However, it is of interest to note that studies of treatment-resistent hypertension 26,27 performed in our wave 6 sample of participants, found that the only class of medication for which cognitive performance (Global Composite and Working Memory), was above the mean and superior relative to other classes of medication was the Angiotensin II receptor blocker class.…”

Section: Discussionmentioning

confidence: 99%

Measurement-to-Measurement Blood Pressure Variability Is Related to Cognitive Performance

et al. 2014

View full text Add to dashboard Cite

The objective was to investigate the association between variability in blood pressure and cognitive function for sitting, standing and reclining blood pressure values, and variability derived from all 15 measures. In previous studies only sitting blood pressure values have been examined, and only a few cognitive measures have been employed. A secondary objective was to examine associations between blood pressure variability and cognitive performance in hypertensive individuals stratified by treatment success. Cross-sectional analyses were performed on 972 participants of the Maine Syracuse Study for whom 15 serial blood pressure clinic measures (5 sitting, 5 recumbant and 5 standing) were obtained, prior to testing of cognitive performance. Using all 15 measures, higher variability in systolic and diastolic blood pressure was associated with poorer performance on multiple measures of cognitive performance, independent of demographic factors, cardiovascular risk factors, and pulse pressure. When sitting, reclining and standing systolic blood pressure values were compared, only variability in standing blood pressure was related to measures of cognitive performance. However, for diastolic blood pressure, variability in all three positions was related to cognitive performance. Mean blood pressure values were weaker predictors of cognition. Furthermore, higher overall variability in both systolic and diastolic blood pressure was associated with poorer cognitive performance in unsuccessfully treated hypertensive individuals (with blood pressure ≥140/90 mmHg), but these associations were not evident in those with controlled hypertension.

show abstract

“…Several studies suggested an involvement of the renin-angiotensin system (RAS) and ACE on cognitive performance, as improved cognition and delayed dementia progression were associated with the use of ACE inhibitors (Ohrui et al, 2004;Kehoe and Wilcock, 2007;Yamada et al, 2011;Gao et al, 2013). Thus, considering that cognitive impairments are central features of SCZ (Kahn and Keefe, 2013), these results might direct future studies on the ACE roles on cognition in SCZ patients.…”

Section: Discussionmentioning

confidence: 87%

ACE I/D genotype-related increase in ACE plasma activity is a better predictor for schizophrenia diagnosis than the genotype alone

Gadelha

Yonamine

Ota

et al. 2015

Schizophrenia Research

View full text Add to dashboard Cite

Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats

Cited by 50 publications

References 50 publications

Pharmarcogenetic Mechanism of ACE I/D Polymorphism Adversely Responding to ACE Inhibitors in Regulating the ACE Promoter Activity in Neurons

Pharmarcogenetic Mechanism of ACE I/D Polymorphism Adversely Responding to ACE Inhibitors in Regulating the ACE Promoter Activity in Neurons

Measurement-to-Measurement Blood Pressure Variability Is Related to Cognitive Performance

ACE I/D genotype-related increase in ACE plasma activity is a better predictor for schizophrenia diagnosis than the genotype alone

Contact Info

Product

Resources

About